<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>D-dimer biomarkers &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/d-dimer-biomarkers/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 06 Sep 2025 09:33:31 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>D-dimer biomarkers &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Venous Thrombosis Risk in New Lymphoma Patients</title>
		<link>https://bioengineer.org/venous-thrombosis-risk-in-new-lymphoma-patients/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 11 Aug 2025 13:41:49 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[D-dimer biomarkers]]></category>
		<category><![CDATA[Khorana score validation]]></category>
		<category><![CDATA[Lymphoma thrombosis risk factors]]></category>
		<category><![CDATA[Southeast Asia oncology research]]></category>
		<category><![CDATA[Venous thromboembolism in lymphoma]]></category>
		<guid isPermaLink="false">https://bioengineer.org/venous-thrombosis-risk-in-new-lymphoma-patients/</guid>

					<description><![CDATA[In a groundbreaking study emerging from the Vietnam National Cancer Hospital, researchers have unveiled pivotal insights into the incidence and risk factors of venous thromboembolism (VTE) among newly diagnosed lymphoma patients undergoing systemic therapy. VTE, a term encompassing both deep vein thrombosis and pulmonary embolism, remains a formidable complication frequently exacerbating morbidity and mortality in [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">255002</post-id>	</item>
	</channel>
</rss>
